MLH1 methylation screening is effective in identifying epimutation carriers. Eur J Hum Genet

Hereditary Cancer Program, Catalan Institute of Oncology, ICO-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
European journal of human genetics: EJHG (Impact Factor: 4.35). 07/2012; 20(12)(12). DOI: 10.1038/ejhg.2012.136
Source: PubMed


Recently, constitutional MLH1 epimutations have been identified in a subset of Lynch syndrome (LS) cases. The aim of this study was the identification of patients harboring constitutional MLH1 epimutations in a set of 34 patients with a clinical suspicion of LS, MLH1-methylated tumors and non-detected germline mutations in mismatch repair (MMR) genes. MLH1 promoter methylation was analyzed in lymphocyte DNA samples by MS-MLPA (Methylation-specific multiplex ligation-dependent probe amplification). Confirmation of MLH1 constitutional methylation was performed by MS-MCA (Methylation-specific melting curve analysis), bisulfite sequencing and pyrosequencing in different biological samples. Allelic expression was determined using heterozygous polymorphisms. Vertical transmission was evaluated by MS-MLPA and haplotype analyses. MS-MLPA analysis detected constitutional MLH1 methylation in 2 of the 34 individuals whose colorectal cancers showed MLH1 methylation (5.9%). These results were confirmed by bisulfite-based methods. Both epimutation carriers had developed metachronous early-onset LS tumors, with no family history of LS-associated cancers in their first-degree relatives. In one of the cases, the identified MLH1 constitutional methylation was monoallelic and results in MLH1 and EPM2AIP1 allele-specific transcriptional silencing. It was present in normal somatic tissues and absent in spermatozoa. The methylated MLH1 allele was maternally transmitted and methylation was reversed in a daughter who inherited the same allele. MLH1 methylation screening in lymphocyte DNA from patients with early-onset MLH1-methylated LS-associated tumors allows the identification of epimutation carriers. The present study adds further evidence to the emerging entity of soma-wide MLH1 epimutation and its heritability.European Journal of Human Genetics advance online publication, 4 July 2012; doi:10.1038/ejhg.2012.136.

Download full-text


Available from: Ester Borràs, Mar 17, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Lynch syndrome, characterised by an autosomal dominant predisposition to the development of young-onset colorectal, endometrial and additional cancers exhibiting the microsatellite instability phenotype, is typically caused by heterozygous germline mutations within one of the DNA mismatch repair genes. The MLH1 and MSH2 genes are the most frequently mutated of the mismatch repair genes. Until the turn of this century, no pathogenic mutation could be identified in up to one third of cases with a strong clinical suspicion of Lynch syndrome, but screens for disease-causing mutations within alternative genes were largely fruitless. In the past decade, an alternative aetiological mechanism for the development Lynch syndrome-­related cancers emerged, which involved epigenetic-based dysregulation of the two key mismatch repair genes MLH1 and MSH2. Termed a constitutional epimutation, this type of defect manifests as methylation of a single allele of the CpG island promoter accompanied by transcriptional inactivation of the affected allele within normal somatic tissues, in the context of a normal gene sequence. MSH2 epimutations are caused by linked germline deletions of the neighbouring EPCAM gene, although MSH2 itself remains intact, and demonstrate classic dominant inheritance. However MLH1 epimutations can arise spontaneously in the carrier and are reversible between generations, resulting in unpredictable non-Mendelian patterns of inheritance, or display dominant inheritance with particular genetic alleles due to the presence of a linked genetic alteration within or nearby MLH1. Constitutional epimutations are thus associated with complex underlying mechanisms, and furthermore, give rise to atypical cases of Lynch syndrome both in terms of phenotypic heterogeneity and the risk of intergenerational transmission. This confounds molecular diagnosis, clinical management and genetic counselling of carriers and their families. As more information emerges from clinical and molecular research in this nascent field, tailored management strategies need to be devised so patients can realise the benefits of these discoveries.
    DNA Alterations in Lynch Syndrome, 01/2013: pages 101-133; , ISBN: 978-94-007-6596-2
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recognition by Warthin of the familial clustering of colorectal and gynaecological cancers a century ago laid the foundation for the recognition of familial cancer. By tracking afflicted pedigrees, Lynch defined the clinical characteristics and argued for a heritable genetic component to this autosomal dominant cancer susceptibility condition, now termed Lynch syndrome. This was proven in the 1990s, with the discovery of deleterious germline mutations of the mismatch repair genes as its cause. Yet despite the genetic revolution at the turn of the twenty-first century, no pathogenic mutation was identifiable in approximately one-third of cases with suspected Lynch syndrome. In the past decade, the alternative mechanism of constitutional epimutation of the two major mismatch repair genes, MLH1 and MSH2, was identified in a proportion of these outstanding cases. This epigenetic defect, characterized by methylation and transcriptional inactivation of a single genetic allele within normal tissues, predisposes to the development of Lynch-type cancers. MSH2 and some MLH1 epimutations have been linked to genetic alterations within their vicinity and demonstrate dominant inheritance, whilst other MLH1 epimutations are reversible between generations and demonstrate non-Mendelian inheritance. This review charts the discovery of mismatch repair epimutations, their aetiological role in Lynch syndrome and the mechanistic basis for their variable inheritance patterns.
    Familial Cancer 03/2013; 12(2). DOI:10.1007/s10689-013-9613-3 · 1.98 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Germline mutations of the DNA mismatch repair genes MLH1, MSH2, MSH6 or PMS2, and deletions affecting the EPCAM gene adjacent to MSH2, underlie Lynch syndrome by predisposing to early-onset colorectal, endometrial and other cancers. An alternative but rare cause of Lynch syndrome is constitutional epimutation of MLH1, whereby promoter methylation and transcriptional silencing of one allele occurs throughout normal tissues. A dominantly transmitted constitutional MLH1 epimutation has been linked to an MLH1 haplotype bearing two single-nucleotide variants, NM_000249.2: c.-27C>A and c.85G>T, in a Caucasian family with Lynch syndrome from Western Australia. Subsequently, a second seemingly unrelated Caucasian Australian case with the same MLH1 haplotype and concomitant epimutation was reported. We now describe three additional, ostensibly unrelated, cancer-affected families of European heritage with this MLH1 haplotype in association with constitutional epimutation, bringing the number of index cases reported to five. Array-based genotyping in four of these families revealed shared haplotypes between individual families that extended across ≤2.6-≤6.4 megabase regions of chromosome 3p, indicating common ancestry. A minimal ≤2.6 megabase founder haplotype common to all four families was identified, which encompassed MLH1 and additional flanking genes and segregated with the MLH1 epimutation in each family. Our findings indicate that the MLH1 c.-27C>A and c.85G>T variants are borne on a European ancestral haplotype and provide conclusive evidence for its pathogenicity via a mechanism of epigenetic silencing of MLH1 within normal tissues. Additional descendants bearing this founder haplotype may exist who are also at high risk of developing Lynch syndrome-related cancers.European Journal of Human Genetics advance online publication, 2 October 2013; doi:10.1038/ejhg.2013.200.
    European journal of human genetics: EJHG 10/2013; 22(5). DOI:10.1038/ejhg.2013.200 · 4.35 Impact Factor
Show more